An Integrative Approach to Hypertension: A Comprehensive Review of Antihypertensive Nutrients and Botanicals
Michelle D Adams, BS, MHSNc
Michael J Gonzalez, NMD, DSc, PhD, FACN
Jorge R Miranda-Massari, PharmD
Jorge Duconge, PhD
Jose R Rodriguez-Gomez, MD, DSc, PhD
Miguel J Berdiel, MD
Kenneth Cintron, MD, FAAOS, ABoIM
PDF
HTML

Keywords

Blood pressure
Botanicals
Hypertension
Minerals
Nutrients
Orthomolecular medicine
Vitamins
PDF
HTML

Abstract

Objective: We conducted a comprehensive review of the most current data available on the antihypertensive effects of 29 different nutraceuticals.

Design: In this review, we collected evidence from clinical trials and meta-analyses of clinical trials with human subjects that are representative of the general adult population; studies of infants, children, and pregnant women were excluded. Observational studies were included in some cases as supplementary evidence, and in vitro or animal studies were included only for the purpose of explaining hypotensive mechanisms. PubMed served as the primary search engine.

Outcome measures: The efficacy of each nutrient and botanical was demonstrated by a treatment that resulted in a reduction of either systolic or diastolic blood pressure in humans.

Results: All of the reviewed botanical and nutrient supplements, with the exception of French maritime pine bark extract and maitake (Grifola frondosa), have been demonstrated to effectively lower blood pressure in humans with good tolerability.

Conclusions: Current data supporting the use of nutrients and botanicals in the treatment of blood pressure are encouraging.

PDF
HTML

References

Nwankwo T, Yoon SS, Burt V, Gu Q. Hypertension among adults in the United States: National Health and Nutrition Examination Survey, 2011–2012. NCHS Data Brief. 2013; 133:1–8.
Mozzafarian D, Benjamin EJ, Go AS, et al. Heart disease and stroke statistics – 2015 update: a report from the American Heart Association. Circulation. 2015; 131:e29–322.
Carretero OA, Oparil S. Essential hypertension. Part I: definition and etiology. Circulation. 2000; 101:329–35.
Chiong JR, Aronow WS, Khan IA, et al. Secondary hypertension: current diagnosis and treatment. Int J Cardiol. 2008; 124:6–21.
Mayo Clinic Staff. High blood pressure (hypertension). http://www.mayoclinic.org/diseases-conditions/high-blood-pressure/basics/definition/con-20019580. Accessed April 26, 2016 .
Mann JFE. Patient information: high blood pressure treatment in adults (beyond the basics). UpToDate [updated April 18, 2016]. http://www.uptodate.com/contents/high-blood-pressure-treatment-in-adults-beyond-the-basics. Accessed April 26, 2016 .
Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. Br Med J. 2009; 338:b1665.
Diao D, Wright JM, Cundiff DK, Gueyffier F. Pharmacotherapy for mild hypertension. Cochrane Database Syst Rev. 2012; 8:CD006742.
Centers for Disease Control and Prevention (CDC). Vital signs: awareness and treatment of uncontrolled hypertension among adults – United States, 2003–2010. MMWR Morb Mortal Wkly Rep. 2012; 61:703–9.
Go AS, Mozaffarian D, Roger VL, et al. Heart disease and stroke statistics – 2014 update: a report from the American Heart Association. Circulation. 2014; 129:e28–292.
Guerrero L, Castillo J, Quiñones M, et al. Inhibition of angiotensin-converting enzyme activity by flavonoids: structure-activity relationship studies. PLoS One. 2012; 7:e49493.
Herrera-Arellano A, Flores-Romero S, Chávez-Soto MA, Tortoriello J. Effectiveness and tolerability of a standardized extract from Hibiscus sabdariffa in patients with mild to moderate hypertension: a controlled and randomized clinical trial. Phytomedicine. 2004; 11:375–82.
Ojeda D, Jiménez-Ferrer E, Zamilpa A, et al. Inhibition of angiotensin converting enzyme (ACE) activity by the anthocyanins delphinidin- and cyanidin-3-O-sambubiosides from Hibiscus sabdariffa. J Ethnopharmacol. 2010; 127:7–10.
Haji Faraji M, Haji Tarkhani A. The effect of sour tea (Hibiscus sabdariffa) on essential hypertension. J Ethnopharmacol. 1999; 65:231–6.
Herrera-Arellano A, Miranda-Sánchez J, Avila-Castro P, et al. Clinical effects produced by a standardized herbal medicinal product of Hibiscus sabdariffa on patients with hypertension: a randomized, double-blind, lisinopril-controlled clinical trial. Planta Med. 2007; 73:6–12.
Nwachukwu DC, Aneke EI, Obika LF, Nwachukwu NZ. Effects of aqueous extract of Hibiscus sabdariffa on the renin-angiotensin-aldosterone system of Nigerians with mild to moderate essential hypertension: a comparative study with lisinopril. Indian J Pharmacol. 2015; 47:540–5.
Serban C, Sahebkar A, Ursoniu S, et al. Effect of sour tea (Hibiscus sabdariffa L.) on arterial hypertension: a systematic review and meta-analysis of randomized controlled trials. J Hypertens. 2015; 33:1119–27.
Parichatikanond W, Pinthong D, Mangmool S. Blockade of the renin-angiotensin system with delphinidin, cyanin, and quercetin. Planta Med. 2012; 78:1626–32.
Cassidy A, O’Reilly ÉJ, Kay C, et al. Habitual intake of flavonoid subclasses and incident hypertension in adults. Am J Clin Nutr. 2011; 93:338–47.
Cassidy A, Mukamal KJ, Liu L, et al. High anthocyanin intake is associated with a reduced risk of myocardial infarction in young and middle-aged women. Circulation. 2013; 127:188–96.
Jennings A, Welch AA, Fairweather-Tait SJ, et al. Higher anthocyanin intake is associated with lower arterial stiffness and central blood pressure in women. Am J Clin Nutr. 2012; 96:781–8.
Takahashi S, Tanaka H, Hano Y, et al. Hypotensive effect in rats of hydrophilic extract from Terminalia arjuna containing tannin-related compounds. Phytother Res. 1997; 11:424–7.
Dwivedi S, Chansouria JPN, Somani PN, Udupa KN. Effect of Terminalia arjuna on ischaemic heart disease. Altern Med. 1989; 3:115–22.
Ygnanarayan R, Sangle SA, Sirsikar SS, Mitra DK. Regression of cardiac hypertrophy in hypertensive patients – comparison of abana with propranolol. Phytother Res. 1997; 11:257–59.
Dehkhordi FR, Kamkhah AF. Antihypertensive effect of Nigella sativa seed extract in patients with mild hypertension. Fundam Clin Pharmacol. 2008; 22:447–52.
Huseini HF. Blood pressure lowering effect of Nigella sativa L. seed oil in healthy volunteers: a randomized, double-blind, placebo-controlled clinical trial. Phytother Res. 2013; 27:1849–53.
Ghosheh OA, Houdi AA, Crooks PA. High performance liquid chromatographic analysis of the pharmacologically active quinones and related compounds in the oil of the black seed (Nigella sativa L.). J Pharm Biomed Anal. 1999; 19:757–62.
Jaarin K, Foong WD, Yeoh MH, et al. Mechanisms of the antihypertensive effects of Nigella sativa oil in L-NAME-induced hypertensive rats. Clinics (Sao Paolo). 2015; 70:751–7.
El Tahir KEH, Al Ajmiand M, Al-Bekari AM. Some cardiovascular effects of dethymoquinonated Nigella sativa volatile oil and its major components α-pinene and p-cymene in rats. Saudi Pharm J. 2003; 11:104–10.
Magyar J, Szentandrássy N, Bányász T, et al. Effects of terpenoid phenol derivatives on calcium current in canine and human ventricular cardiomyocytes. Eur J Pharmacol. 2004; 487:29–36.
Niazmand S, Fereidouni E, Mahmoudabady M, Mousavi SM. Endothelium-independent vasorelaxant effects of hydroalcoholic extract from Nigella sativa seed in rat aorta: the roles of Ca2+ and K+ channels. Biomed Res Int. 2014; 2014:247054.
Witteman JC, Willett WC, Stampfer MJ, et al. A prospective study of nutritional factors and hypertension among US women. Circulation. 1989; 80:1320–27.
Ascherio A, Rimm EB, Giovannucci EL, et al. A prospective study of nutritional factors and hypertension among US men. Circulation. 1992; 86:1475–84.
Wang L, Manson JE, Buring JE, et al. Dietary intake of dairy products, calcium, and vitamin D and the risk of hypertension in middle-aged and older women. Hypertension. 2008; 51:1073–9.
Bucher HC, Cook RJ, Guyatt GH, et al. Effects of dietary calcium supplementation on blood pressure: a meta-analysis of randomized controlled trials. J Am Med Assoc. 1996; 275:1016–22.
Allender PS, Cutler JA, Follmann D, et al. Dietary calcium and blood pressure: a meta-analysis of randomized clinical trials. Ann Intern Med. 1996; 124:825–31.
Whelton PK, Appel L, Charleston J, et al. The effects of nonpharmacologic interventions on blood pressure of persons with high normal levels: Results of the Trials of Hypertension Prevention, Phase I [published erratum appears in J Am Med Assoc. 1992;267:2330]. J Am Med Assoc. 1992; 267:1213–20.
Griffith LE, Guyatt GH, Cook RJ, et al. The influence of dietary and non-dietary calcium supplementation on blood pressure: an updated meta-analysis of randomized clinical trials. Am J Hypertens. 1999; 12:84–92.
Cormick G, Ciapponi A, Cafferata ML, Belizán JM. Calcium supplementation for prevention of primary hypertension. Cochrane Database Syst Rev. 2015; 6:CD010037.
Undurti DN. Nutritional factors in the pathobiology of human essential hypertension. Nutrition. 2001; 17:337–46.
Waliszewski KN, Blasco G. Nutraceutical properties of lycopene [in Spanish]. Salud Publica Mex. 2010; 52:254–65.
Li X, Xu J. Lycopene supplement and blood pressure: an updated meta-analysis of intervention trials. Nutrients. 2013; 5:3696–712.
Hozawa A, Jacobs DR Jr, Steffes MW, et al. Circulating carotenoid concentrations and incident hypertension: the Coronary Artery Risk Development in Young Adults (CARDIA) study. J Hypertens. 2009; 27:237–42.
Chen J, He J, Hamm L, et al. Serum antioxidant vitamins and blood pressure in the United States population. Hypertension. 2002; 40:810–6.
Parslow RA, Sachdev P, Salonikas C, et al. Associations between plasma antioxidants and hypertension in a community-based sample of 415 Australians aged 60–64. J Hum Hypertens. 2005; 19:219–26.
Paran E, Novack V, Engelhard YN, Hazan-Halevy I. The effects of natural antioxidants from tomato extract in treated but uncontrolled hypertensive patients. Cardiovasc Drugs Ther. 2009; 23:145–51.
Engelhard YN, Gazer B, Paran E. Natural antioxidants from tomato extract reduce blood pressure in patients with grade-1 hypertension: a double-blind, placebo-controlled pilot study. Am Heart J. 2006; 151:100.
Kim JY, Paik JK, Kim OY, et al. Effects of lycopene supplementation on oxidative stress and markers of endothelial function in healthy men. Atherosclerosis. 2011; 215:189–95.
Ried K, Frank OR, Stocks NP. Dark chocolate or tomato extract for prehypertension: a randomised controlled trial. BMC Complement Altern Med. 2009; 9:22.
Ried K, Fakler P. Protective effect of lycopene on serum cholesterol and blood pressure: meta-analyses of intervention trials. Maturitas. 2011; 68:299–310.
Zhao Y, Wang J, Ballevre O, et al. Antihypertensive effects and mechanisms of chlorogenic acids. Hypertens Res. 2012; 35:370–4.
Kozuma K, Tsuchiya S, Kohori J, et al. Antihypertensive effect of green coffee bean extract on mildly hypertensive subjects. Hypertens Res. 2005; 28:711–8.
Watanabe T, Arai Y, Mitsui Y, et al. The blood pressure-lowering effect and safety of chlorogenic acid from green coffee bean extract in essential hypertension. Clin Exp Hypertens. 2006; 28:439–49.
Onakpoya IJ, Spencer EA, Thompson MJ, Heneghan CJ. The effect of chlorogenic acid on blood pressure: a systematic review and meta-analysis of randomized clinical trials. J Hum Hypertens. 2015; 29:77–81.
Rosenfeldt F, Hilton D, Pepe S, Krum H. Systematic review of effect of coenzyme Q10 in physical exercise, hypertension and heart failure. Biofactors. 2003; 18:91–100.
Rosenfeldt FL, Haas SJ, Krum H, et al. Coenzyme Q10 in the treatment of hypertension: a meta-analysis of the clinical trials. J Hum Hypertens. 2007; 21:297–306.
Ho MJ, Li EC, Wright JM. Blood pressure lowering efficacy of coenzyme Q10 for primary hypertension. Cochrane Database Syst Rev. 2016; 3:CD007435.
Mojiminiyi FB, Owolabi ME, Igbokwe UV, Ajagbonna OP. The vasorelaxant effect of Viscum album leaf extract is mediated by calcium-dependent mechanism. Niger J Physiol Sci. 2008; 23:115–20.
Poruthukaren KJ, Palatty PL, Baliga MS, Suresh S. Clinical evaluation of Viscum album mother tincture as an antihypertensive: a pilot study. J Evid Based Complementary Altern Med. 2014; 19:31–5.
Miller PE, Van Elswyk M, Alexander DD. Long-chain omega-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid and blood pressure: a meta-analysis of randomized controlled trials. Am J Hypertens. 2014; 27:885–96.
Campbell F, Dickinson HO, Critchley JA, et al. A systematic review of fish-oil supplements for the prevention and treatment of hypertension. Eur J Prev Cardiol. 2013; 20:107–20.
Cabo J, Alonso R, Mata P. Omega-3 fatty acids and blood pressure. Br J Nutr. 2012; 107:195–200.
Geleijnse JM, Giltay EJ, Grobbee DE, et al. Blood pressure response to fish oil supplementation: meta-regression analysis of randomized trials. J Hypertens. 2002; 20:1493–9.
Morris MC, Sacks F, Rosner B. Does fish oil lower blood pressure? A meta-analysis of controlled trials. Circulation. 1993; 88:523–33.
Brader L, Uusitupa M, Dragsted LO, Hermansen K. Effects of an isocaloric healthy Nordic diet on ambulatory blood pressure in metabolic syndrome: a randomized SYSDIET sub-study. Eur J Clin Nutr. 2014; 68:57–63.
Adamsson V, Reumark A, Fredriksson IB, et al. Effects of a healthy Nordic diet on cardiovascular risk factors in hypercholesterolaemic subjects: a randomized controlled trial (NORDIET). J Intern Med. 2011; 269:150–9.
Nyby MD, Matsumoto K, Yamamoto K, et al. Dietary fish oil prevents vascular dysfunction and oxidative stress in hyperinsulinemic rats. Am J Hypertens. 2005; 18:213–9.
Knapp HR, FitzGerald GA. The antihypertensive effects of fish oil: a controlled study of polyunsaturated fatty acid supplements in essential hypertension. N Engl J Med. 1989; 320:1037–43.
Knapp HR. n-3 fatty acids and human hypertension. Curr Opin Lipidol. 1996; 7:30–3.
Raimondi L, Lodovici M, Visioli F, et al. n-3 polyunsaturated fatty acids supplementation decreases asymmetric dimethyl arginine and arachidonate accumulation in aging spontaneously hypertensive rats. Eur J Nutr. 2005; 44:327–33.
Das UN. Beneficial effect(s) of n-3 fatty acids in cardiovascular diseases: but, why and how? Prostaglandins Leukot Essent Fatty Acids. 2000; 63:351–62.
Rohdewald P. A review of the French maritime pine bark extract (Pycnogenol), a herbal medication with a diverse clinical pharmacology. Int J Clin Pharmacol Ther. 2002; 40:158–68.
Nishioka K, Hidaka T, Nakamura S, et al. Pycnogenol®, French maritime pine bark extract, augments endothelium-dependent vasodilation in humans. Hypertens Res. 2007; 30:775–80.
Rohner A, Ried K, Sobenin IA, et al. A systematic review and meta-analysis on the effects of garlic preparations on blood pressure in individuals with hypertension. Am J Hypertens. 2015; 28:414–23.
Wang HP, Yang J, Qin LQ, Yang XJ. Effect of garlic on blood pressure: a meta-analysis. J Clin Hypertens. 2015; 17:223–31.
Reinhart KM, Coleman CI, Teevan C, et al. Effects of garlic on blood pressure in patients with and without systolic hypertension: a meta-analysis. Ann Pharmacother. 2008; 42:1766–71.
Ried K, Frank OR, Stocks NP, et al. Effect of garlic on blood pressure: a systematic review and meta-analysis. BMC Cardiovasc Disord. 2008; 8:13.
Xiong XJ, Wang PQ, Li SJ, et al. Garlic for hypertension: a systematic review and meta-analysis of randomized controlled trials. Phytomedicine. 2015; 22:352–61.
Shouk R, Abdou A, Shetty K, et al. Mechanisms underlying the antihypertensive effects of garlic bioactives. Nutr Res. 2014; 34:106–15.
Feringa HH, Laskey DA, Dickson JE, Coleman CI. The effect of grape seed extract on cardiovascular risk markers: a meta-analysis of randomized controlled trials. J Am Diet Assoc. 2011; 111:1173–81.
Park E, Edirisinghe I, Choy YY, et al. Effects of grape seed extract beverage on blood pressure and metabolic indices in individuals with pre-hypertension: a randomised, double-blinded, two-arm, parallel, placebo-controlled trial. Br J Nutr. 2016; 115:226–38.
Ras RT, Zock PL, Zebregs YE, et al. Effect of polyphenol-rich grape seed extract on ambulatory blood pressure in subjects with pre- and stage I hypertension. Br J Nutr. 2013; 110:2234–41.
Walker AF, Marakis G, Simpson E, et al. Hypotensive effects of hawthorn for patients with diabetes taking prescription drugs: a randomised controlled trial. Br J Gen Pract. 2006; 56:437–43.
Asgary S, Naderi G, Sadeghi M, et al. Antihypertensive effect of Iranian Crataegus curvisepala Lind.: a randomized, double-blind study. Drugs Exp Clin Res. 2004; 30:221–5.
Quettier-Deleu C, Voiselle G, Fruchart JC, et al. Hawthorn extracts inhibit LDL oxidation. Pharmazie. 2003; 58:577–81.
Brixius K, Willms S, Napp A, et al. Crataegus special extract WS 1442 induces an endothelium-dependent, NO-mediated vasorelaxation via eNOS-phosphorylation at serine 1177. Cardiovasc Drugs Ther. 2006; 20:177–84.
Erfurt L, Schandry R, Rubenbauer S, Braun U. The effects of repeated administration of camphor-Crataegus berry extract combination on blood pressure and on attentional performance – a randomized, placebo-controlled, double-blind study. Phytomedicine. 2014; 21:1349–55.
Schandry R, Duschek S. The effect of camphor–Crataegus berry extract combination on blood pressure and mental functions in chronic hypotension – a randomized placebo controlled double blind design. Phytomedicine. 2008; 15:914–22.
Hempel B, Kroll M, Schneider B. Efficacy and safety of a herbal drug containing hawthorn berries and D-camphor in hypotension and orthostatic circulatory disorders/results of a retrospective epidemiologic cohort study [in German]. Arzneimittelforschung. 2005; 55:443–50.
Dong JY, Qin LQ, Zhang Z, et al. Effect of oral L-arginine supplementation on blood pressure: a meta-analysis of randomized, double-blind, placebo-controlled trials. Am Heart J. 2011; 162:959–65.
Lorin J, Zeller M, Guilland JC, et al. Arginine and nitric oxide synthase: regulatory mechanisms and cardiovascular aspects. Mol Nutr Food Res. 2014; 58:101–16.
Quyyumi AA, Dakak N, Diodati JG, et al. Effect of L-arginine on human coronary endothelium-dependent and physiologic vasodilation. J Am Coll Cardiol. 1997; 30:1220–7.
Lerman A, Burnett JCJ, Higano ST, et al. Long-term L-arginine supplementation improves small-vessel coronary endothelial function in humans. Circulation. 1998; 97:2123–8.
Geleijnse JM, Witteman JC, den Breeijen JH, et al. Dietary electrolyte intake and blood pressure in older subjects: the Rotterdam Study. J Hypertens. 1996; 14:737–41.
Yang CY, Chiu HF. Calcium and magnesium in drinking water and the risk of death from hypertension. Am J Hypertens. 1999; 12:894–9.
Fox C, Ramsoomair D, Mahoney M, et al. An investigation of hypomagnesemia among ambulatory urban African-Americans. J Fam Practice. 1999; 48:635–9.
Joffres M, Reed D, Yano K. Relationship of magnesium intake and other dietary factors to blood pressure: the Honolulu Heart Study. Am J Clin Nutr. 1987; 45:469–75.
Ascherio A, Hennekens C, Willet WC, et al. Prospective study of nutrtional factors, blood pressure, and hypertension among US women. Hypertension. 1996; 27:1065–72.
Colditz G, Manson J, Stampfer M. Diet and risk of clinical diabetes in women. Am J Clin Nutr. 1993; 55:1018–23.
Steyn K, Jooste P. Hypertension in the coloured population of the Cape Peninsula. S Afr Med J. 1986; 69:165–9.
Touyz RM, Milne FJ, Reinach SG. Racial differences in cell membrane ATPases and cellular cation content in urban South African normotensive and hypertensive subjects. Am J Hypertens. 1993; 6:693–700.
Van Leer EM, Seidell JC, Kromhout D. Dietary calcium, potassium, magnesium, and blood pressure in the Netherlands. Int J Epidemiol. 1995; 24:1117–23.
Fox C, Mahoney MC, Rasoomair D, Carter CA. Magnesium deficiency in African-Americans: does it contribute to increased cardiovascular risk factors? J Natl Med Assoc. 2003; 95:257–62.
Jee SH, Miller ER, Guallar E, et al. The effect of magnesium supplementation on blood pressure: a meta-analysis of randomized clinical trials. Am J Hypertens. 2002; 15:691–6.
Sontia B, Touyz RM. Role of magnesium in hypertension. Arch Biochem Biophys. 2007; 458:33–9.
Mayell M. Maitake extracts and their therapeutic potential – a review. Altern Med Rev. 2001; 6:48–60.
Scheer F, Montfrans G, van Someren E, et al. Daily nighttime melatonin reduces blood pressure in male patients with essential hypertension. Hypertension. 2004; 43:192–7.
Koziróg M, Poliwczak AR, Duchnowicz P, et al. Melatonin treatment improves blood pressure, lipid profile, and parameters of oxidative stress in patients with metabolic syndrome. J Pineal Res. 2011; 50:261–6.
Obayashi K, Saeki K, Tone N, Kurumatani N. Relationship between melatonin secretion and nighttime blood pressure in elderly individuals with and without antihypertensive treatment: a cross-sectional study of the HEIJO-KYO cohort. Hypertens Res. 2014; 37:908–13.
Reiter RJ, Tan DX, Rosales-Corral S, Manchester LC. The universal nature, unequal distribution and antioxidant functions of melatonin and its derivatives. Mini Rev Med Chem. 2013; 13:373–84.
Galano A, Tan DX, Reiter RJ. On the free radical scavenging activities of melatonin’s metabolites, AFMK and AMK. J Pineal Res. 2013; 54:245–57.
Scheffler A, Rauwald HW, Kampa B, et al. Olea europaea leaf extract exerts L-type Ca2+ channel antagonistic effects. J Ethnopharmacol. 2008; 120:233–40.
Zarzuelo A, Duarte J, Jiménez J, et al. Vasodilator effect of olive leaf. Planta Med. 1991; 57:417–9.
Khayyal MT, el-Ghazaly MA, Abdallah DM, et al. Blood pressure lowering effect of an olive leaf extract (Olea europaea) in L-NAME induced hypertension in rats. Arzneimittelforschung. 2002; 52:797–802.
Sabry OMM. Review: beneficial health effects of olive leaves extracts. J Nat Sci Res. 2014; 4:1–9.
Cherif S, Rahal N, Haouala M, et al. A clinical trial of a titrated Olea extract in the treatment of essential arterial hypertension [in French]. J Pharm Belg. 1996; 51:69–71.
Lockyer S, Rowland I, Spencer JPE, et al. Impact of phenolic-rich olive leaf extract on blood pressure, plasma lipids and inflammatory markers: a randomised controlled trial. Eur J Nutr. 2016:1–12. doi:10.1007/s00394-016-1188-y .
Cabrera-Vique C, Navarro-Alarcón M, Rodríguez Martínez C, Fonollá-Joya J. Hypotensive effect of an extract of bioactive compounds of olive leaves: preliminary clinical study [in Spanish]. Nutr Hosp. 2015; 32:242–9.
Susalit E, Agus N, Effendi I, et al. Olive (Olea europaea) leaf extract effective in patients with stage-1 hypertension: comparison with Captopril. Phytomedicine. 2011; 18:251–8.
Perrinjaquet-Moccetti T, Busjahn A, Schmidlin C, et al. Food supplementation with an olive (Olea europaea L.) leaf extract reduces blood pressure in borderline hypertensive monozygotic twins. Phytother Res. 2008; 22:1239–42.
Wong RH, Garg ML, Wood LG, Howe PR. Antihypertensive potential of combined extracts of olive leaf, green coffee bean and beetroot: a randomized, double-blind, placebo-controlled crossover trial. Nutrients. 2014; 6:4881–94.
Asgary S, Keshvari M, Sahebkar A, et al. Clinical investigation of the acute effects of pomegranate juice on blood pressure and endothelial function in hypertensive individuals. ARYA Atheroscler. 2013; 9:326–31.
Asgary S, Sahebkar A, Afshani MR, et al. Clinical evaluation of blood pressure lowering, endothelial function improving, hypolipidemic and anti-inflammatory effects of pomegranate juice in hypertensive subjects. Phytother Res. 2014; 28:193–9.
Shema-Didi L, Kristal B, Sela S, et al. Does pomegranate intake attenuate cardiovascular risk factors in hemodialysis patients? Nutr J. 2014; 13:18.
Aviram M, Rosenblat M, Gaitini D, et al. Pomegranate juice consumption for 3 years by patients with carotid artery stenosis reduces common carotid intima-media thickness, blood pressure and LDL oxidation. Clin Nutr. 2004; 23:423–33.
Mohan M, Waghulde H, Kasture S. Effect of pomegranate juice on angiotensin II-induced hypertension in diabetic Wistar rats. Phytother Res. 2010; 24(Suppl 2):S196–203.
Aviram M, Dornfeld L. Pomegranate juice consumption inhibits serum angiotensin converting enzyme activity and reduces systolic blood pressure. Atherosclerosis. 2001; 158:195–8.
de Nigris F, Balestrieri ML, Williams-Ignarro S, et al. The influence of pomegranate fruit extract in comparison to regular pomegranate juice and seed oil on nitric oxide and arterial function in obese Zucker rats. Nitric Oxide. 2007; 17:50–4.
Harper KJ, Houston MC. Potassium, magnesium, and calcium: their role in both the cause and treatment of hypertension. J Clin Hypertens. 2008; 10:3–11.
Khaw KT, Barrett-Connor E. Dietary potassium and blood pressure in a population. Am J Clin Nutr. 1984; 39:963–8.
McCarron DA, Morris CD, Henry HJ, Stanton JL. Blood pressure and nutrient intake in the United States. Science. 1984; 224:1392–8.
Cappuccio FP, MacGregor GA. Does potassium supplementation lower blood pressure? A meta-analysis of published trials. J Hypertens. 1991; 9:465–73.
Whelton PK, He J, Cutler JA, et al. Effects of oral potassium on blood pressure: meta-analysis of randomized controlled clinical trials. J Am Med Assoc. 1997; 277:1624–32.
Geleijnse JM, Kok FJ, Grobbee DE. Blood pressure response to changes in sodium and potassium intake: a metaregression analysis of randomised trials. J Hum Hypertens. 2003; 17:471–80.
Dickinson HO, Nicolson DJ, Campbell F, et al. Potassium supplementation for the management of primary hypertensionin adults. Cochrane Database Syst Rev. 2006; 3:CD004641.
Preuss HG. Diet, genetics and hypertension. J Am Coll Nutr. 1997; 16:296–305.
Taddei S, Mattei P, Virdis A, et al. Effect of potassium on vasodilation to acetylcholine in essential hypertension. Hypertension. 1994; 23:485–90.
Penton D, Czogalla J, Loffing J. Dietary potassium and the renal control of salt balance and blood pressure. Pflugers Arch. 2015; 467:513–30.
Gordish KL, Beierwaltes WH. Resveratrol induces acute endothelium-dependent renal vasodilation mediated through nitric oxide and reactive oxygen species scavenging. Am J Physiol Renal Physiol. 2014; 306:542–50.
Zhang H, Morgan B, Potter BJ, et al. Resveratrol improves left ventricular diastolic relaxation in type 2 diabetes by inhibiting oxidative/nitrative stress: in vivo demonstration with magnetic resonance imaging. Am J Physiol Heart Circ Physiol. 2010; 299:H985–94.
Liu Y, Ma W, Zhang P, et al. Effect of resveratrol on blood pressure: a meta-analysis of randomized controlled trials. Clin Nutr. 2015; 34:27–34.
Miyawaki T, Aono H, Toyoda-Ono Y, et al: Antihypertensive effects of sesamin in humans. J Nutr Sci Vitaminol. 2009; 55:87–91.
Wu JH, Hodgson JM, Clarke MW, et al. Inhibition of 20-hydroxyeicosatetraenoic acid synthesis using specific plant lignans: in vitro and human studies. Hypertension. 2009; 54:1151–8.
Liu XX, Li SH, Chen JZ, et al. Effect of soy isoflavones on blood pressure: a meta-analysis of randomized controlled trials. Nutr Metab Cardiovasc Dis. 2012; 22:463–70.
Taku K, Lin N, Cai D, et al. Effects of soy isoflavone extract supplements on blood pressure in adult humans: systematic review and meta-analysis of randomized placebo-controlled trials. J Hypertens. 2010; 28:1971–82.
Welty FK, Lee KS, Lew NS, Zhou JR. Effect of soy nuts on blood pressure and lipid levels in hypertensive, prehypertensive, and normotensive postmenopausal women. Arch Intern Med. 2007; 167:1060–7.
Husain D, Khanna K, Puri S, Haghighizadeh M. Supplementation of soy isoflavones improved sex hormones, blood pressure, and postmenopausal symptoms. J Am Coll Nutr. 2015; 34:42–8.
Rivas M, Garay RP, Escanero JF, et al. Soy milk lowers blood pressure in men and women with mild to moderate essential hypertension. J Nutr. 2002; 132:1900–2.
Clerici C, Nardi E, Battezzati PM, et al. Novel soy germ pasta improves endothelial function, blood pressure, and oxidative stress in patients with type 2 diabetes. Diabetes Care. 2011; 34:1946–8.
Mahn K, Borrás C, Knock GA, et al. Dietary soy isoflavone induced increases in antioxidant and eNOS gene expression lead to improved endothelial function and reduced blood pressure in vivo. FASEB J. 2005; 19:1755–7.
Si H, Liu D. Genistein, a soy phytoestrogen, upregulates the expression of human endothelial nitric oxide synthase and lowers blood pressure in spontaneously hypertensive rats. J Nutr. 2008; 138:297–304.
Wong WW, Taylor AA, Smith EO, et al. Effect of soy isoflavone supplementation on nitric oxide metabolism and blood pressure in menopausal women. Am J Clin Nutr. 2012; 95:1487–94.
Yamori Y, Taguchi T, Hamada A, et al. Taurine in health and diseases: consistent evidence from experimental and epidemiological studies. J Biomed Sci. 2010; 17(Suppl 1):S6.
Kohashi N, Katori R. Decrease of urinary taurine in essential hypertension. Jpn Heart J. 1983; 24:91–102.
Fujita T, Sato Y. Hypotensive effect of taurine: possible involvement of the sympathetic nervous system and endogenous opiates. J Clin Invest. 1988; 82:993–7.
Harada H, Tsujino T, Watari Y, et al. Oral taurine supplementation prevents fructose-induced hypertension in rats. Heart Vessels. 2004; 19:132–6.
Fujita T, Ando K, Noda H, et al. Effects of increased adrenomedullary activity and taurine in young patients with borderline hypertension. Circulation. 1987; 75:525–32.
Militante JD, Lombardini JB. Treatment of hypertension with oral taurine: experimental and clinical studies. Amino Acids. 2002; 23:381–93.
Xu Y, Arneja A, Tappia P, Dhalla N. The potential health benefits of taurine in cardiovascular disease. Exp Clin Cardiol. 2008; 13:57–65.
Moran JP, Cohen L, Greene JM, et al. Plasma ascorbic acid concentrations relate inversely to blood pressure in human subjects. Am J Clin Nutr. 1993; 57:213–7.
Frei B, England L, Ames BN. Ascorbate is an outstanding antioxidant in human blood plasma. Proc Natl Acad Sci USA. 1989; 86:6377–81.
Jackson TS, Xu A, Vita JA, Keaney JF Jr. Ascorbate prevents the interaction of superoxide and nitric oxide only at very high physiological concentrations. Circ Res. 1998; 83:916–22.
Leclerc PC, Proulx CD, Arguin G, et al. Ascorbic acid decreases the binding affinity of the AT1 receptor for angiotensin II. Am J Hypertens. 2008; 21:67–71.
Juraschek SP, Guallar E, Appel LJ, Miller ER. Effects of vitamin C supplementation on blood pressure: a meta-analysis of randomized controlled trials. Am J Clin Nutr. 2012; 95:1079–88.
Kim MK, Sasaki S, Sasazuki S, et al. Lack of long-term effect of vitamin C supplementation on blood pressure. Hypertension. 2002; 40:797–803.
Forman JP, Williams JS, Fisher N. Plasma 25-hydroxyvitamin D and regulation of the renin angiotensin system in humans. Hypertension. 2010; 55:1283–88.
Scragg R, Sowers M, Bell C. Serum 25-hydroxyvitamin D, ethnicity, and blood pressure in the Third National Health and Nutrition Examination Survey. Am J Hypertens. 2007; 20:713–9.
Judd SE, Nanes MS, Ziegler TR, et al. Optimal vitamin D status attenuates the age-associated increase in systolic blood pressure in white Americans: results from the third National Health and Nutrition Examination Survey. Am J Clin Nutr. 2008; 87:136–41.
Martins D, Wolf M, Pan D, et al. Prevalence of cardiovascular risk factors and the serum levels of 25-hydroxyvitamin D in the United States: data from the Third National Health and Nutrition Examination Survey. Arch Intern Med. 2007; 167:1159–65.
Franczyk A, Stolarz-Skrzypek K, Wesołowska A, Czarnecka D. Vitamin D and vitamin D receptor activators in treatment of hypertension and cardiovascular disease. Cardiovasc Hematol Disord Drug Targets. 2014; 14:34–44.
Tamez H, Thadhani RI. Vitamin D and hypertension: an update and review. Curr Opin Nephrol Hypertens. 2012; 21:492–9.
Beveridge LA, Struthers AD, Khan F, et al. Effect of vitamin D supplementation on blood pressure: a systematic review and meta-analysis incorporating individual patient data. JAMA Intern Med. 2015; 175:745–54.
Kunutsor SK, Burgess S, Munroe PB, Khan H. Vitamin D and high blood pressure: causal association or epiphenomenon? Eur J Epidemiol. 2014; 29:1–14.
Elamin MB, Abu Elnour NO, Elamin KB, et al. Vitamin D and cardiovascular outcomes: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2011; 96:1931–42.
Witham MD, Nadir MA, Struthers AD, et al. Effect of vitamin D on blood pressure: a systematic review and meta-analysis. J Hypertens. 2009; 27:1948–54.
Wu SH, Ho SC, Zhong L. Effects of vitamin D supplementation on blood pressure. South Med J. 2010; 103:729–37.
Schurgers LJ, Spronk H, Soute B, et al. Regression of warfarin-induced medial elastocalcinosis by high intake of vitamin K in rats. Blood. 2007; 109:2823–31.
Teperikidis E. Hypotension associated with menaquinone. Am J Health Syst Pharm. 2012; 69:1307–9.
Hartley L, Clar C, Ghannam O, et al. Vitamin K for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2015; 9:CD011148.
Vermeirssen V, Van Camp J, Augustijns P, Verstraete W. Angiotensin-I converting enzyme (ACE) inhibitory peptides derived from pea and whey protein. Meded Rijksuniv Gent Fak Landbouwkd Toegep Biol Wet. 2002; 67:27–30.
Kitts D, Weiler K. Bioactive proteins and peptides from food sources: applications of bioprocesses used in isolation and recovery. Curr Pharm Des. 2003; 9:1309–23.
FitzGerald RJ, Murray BA, Walsh DJ. Hypotensive peptides from milk proteins. J Nutr. 2004; 134:980–8.
Yamamoto N. Antihypertensive peptides derived from food proteins [published erratum appears in Biopolymers. 1997;43:401–2.]. Biopolymers. 1997; 43:129–34.
Ruiz-Gimenez P, Ibanez A, Slaom JB, et al. Antihypertensive properties of lactoferricin B-derived peptides. J Agric Food Chem. 2010; 58:6721–7.
Seppo L, Jauhiainen T, Poussa T, Korpela R. A fermented milk high in bioactive peptides has a blood pressure-lowering effect in hypertensive subjects. Am J Clin Nutr. 2003; 77:326–30.
Kawase M, Hashimoto H, Hosoda M, et al. Effect of administration of fermented milk containing whey protein concentrate to rats and healthy men on serum lipids and blood pressure. J Dairy Sci. 2000; 83:255–63.
Lee YM, Skurk T, Hennig M, Hauner H. Effect of a milk drink supplemented with whey peptides on blood pressurein patients with mild hypertension. Eur J Nutr. 2007; 46:21–7.
Pins J, Keenan JM. Effects of whey peptides on cardiovascular disease risk factors. J Clin Hypertens. 2006; 8:775–82.
Pal S, Ellis V. The chronic effects of whey proteins on blood pressure, vascular function, and inflammatory markers in overweight individuals. Obesity. 2010; 18:1354–9.
Ahmad M, Khan MP, Mukhtar A, et al. Ethnopharmacological survey on medicinal plants used in herbal drinks among the traditional communities of Pakistan. J Ethnopharmacol. 2016; 184:154–86.
Niazmand S, Harandizadeh F, Mahmoudabady M, et al. Mechanism of vasorelaxation induced by Achillea wilhelmsii in rat isolated thoracic aorta. Adv Biomed Res. 2014; 3:91.
Khan AU, Gilani AH. Blood pressure lowering, cardiovascular inhibitory and bronchodilatory actions of Achillea millefolium. Phytother Res. 2011; 25:577–83.
de Souza P, Gasparotto A Jr, Crestani S, et al. Hypotensive mechanism of the extracts and artemetin isolated from Achillea millefolium L. (Asteraceae) in rats. Phytomedicine. 2011; 18:819–25.
Asgary S, Naderi GH, Sarrafzadegan N, et al. Antihypertensive and antihyperlipidemic effects of Achillea wilhelmsii. Drugs Exp Clin Res. 2000; 26:89–93.
Stamler J, Rose G, Stamler R, et al. INTERSALT study findings: public health and medical care implications. Hypertension. 1989; 14:570–7.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY-NC-ND 4.0). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.